Literature DB >> 22661478

Efficacy of intravitreal administrations of linezolid in an experimental model of S. aureus-related endophthalmitis.

Maher Saleh1, Sophie Lefèvre, Niyazi Acar, Tristan Bourcier, Luc Marcellin, Gilles Prévost, Audrey Subilia, David Gaucher, François Jehl.   

Abstract

PURPOSE: To evaluate the efficacy of intravitreal administration of linezolid (LZD) in a rabbit model of Staphylococcus aureus endophthalmitis.
METHODS: Of 40 rabbits studied, 36 of them received 10(2) colony-forming units (CFU) of S. aureus in their right eye before being randomly assigned to the following groups: four groups of 8 animals received 24 hours after the bacterial inoculation, 1, 10, 30 mg of LZD (LZD 1, LZD 10, and LZD 30) or 1 mg of vancomycin (V1), respectively. Four other animals had a sham injection in their infected eye. The 4 remaining animals were used as negative controls. Clinical, bacterial, and histologic assessments were conducted at different endpoints. Animals were euthanized at day 8. The safety profile of intravitreal LZD was assessed by electroretinography in 5 more animals by comparing the recordings in eyes injected with 30 mg of LZD and contralateral control eyes injected with a solution of sterile saline water.
RESULTS: At day 5, the mean inflammatory clinical scores of Nussenblatt were 7.0 ± 1.0, 3.6 ± 0.7, and 3.1 ± 0.8, in the LZD 1, LZD 10, and LZD 30 groups and 3.4 ± 1.7 and 7.5 ± 0 in the V1 and BSS+ groups, respectively (P < 0.05, ANOVA). The corresponding mean bacterial counts in the vitreous (log 10 CFU/mL) were 6.2 ± 6.5, 3.5 ± 3.8, 0, 3.8 ± 4.2, and 7.8 ± 4.9, respectively (P < 0.05, ANOVA). A 30 mg dose of LZD sterilized all the eyes at day 5 and displayed the lowest (best) histologic score (1.5 ± 0.6). Residual LZD concentrations 24 hours after the administration were between 0.1 and 7.2 mg/L LZD 30 group. The half-time of linezolid in the vitreous was 2 hours. There were no differences in the electroretinogram recordings between control eyes and eyes injected with 30 mg of linezolid at days 1 and 14 after the intravitreal injection.
CONCLUSIONS: This is the first evidence of the effectiveness of linezolid for the treatment of experimental staphylococcal endophthalmitis. High ocular concentrations of LZD were needed to obtain a satisfactory bactericidal effect. Linezolid displayed a concentration-dependent killing activity in the eye. Such doses of intravitreal linezolid appeared to be safe for the retinal function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22661478     DOI: 10.1167/iovs.11-8417

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  4 in total

1.  Safety of intravitreal quinupristin/dalfopristin in an animal model.

Authors:  Veronica E Giordano; Sergio E Hernandez-Da Mota; Tania N Adabache-Guel; Armando Castillejos-Chevez; Sonia Corredor-Casas; Samantha M Salinas-Longoria; Rafael Romero-Vera; Juan M Jimenez-Sierra; Jose L Guerrero-Naranjo; Virgilio Morales-Canton
Journal:  Int J Ophthalmol       Date:  2016-03-18       Impact factor: 1.779

2.  Intravitreal linezolid in the management of vancomycin-resistant enterococcal endophthalmitis.

Authors:  Olufemi Emmanuel Babalola
Journal:  Am J Ophthalmol Case Rep       Date:  2020-10-17

Review 3.  Review of Intraocular Pharmacokinetics of Anti-Infectives Commonly Used in the Treatment of Infectious Endophthalmitis.

Authors:  Andrea Luaces-Rodríguez; Miguel González-Barcia; María José Blanco-Teijeiro; María Gil-Martínez; Francisco Gonzalez; Francisco Gómez-Ulla; María-Jesús Lamas; Francisco-Javier Otero-Espinar; Anxo Fernández-Ferreiro
Journal:  Pharmaceutics       Date:  2018-05-29       Impact factor: 6.321

4.  Endophthalmitis caused by gram-positive bacteria resistant to vancomycin: Clinical settings, causative organisms, antimicrobial susceptibilities, and treatment outcomes.

Authors:  Hegde Sharat Shivaramaiah; Nidhi Relhan; Avinash Pathengay; Nitin Mohan; Harry W Flynn
Journal:  Am J Ophthalmol Case Rep       Date:  2018-02-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.